EPO Grants Albajuna HIV Antiviral Fc Fusion Protein Patent EP3621649A2
Summary
The European Patent Office published application EP3621649A2, granting Albajuna Therapeutics, S.L. a patent for Fc-fusion protein derivatives exhibiting dual HIV antiviral and immunomodulatory activity. The patent names inventors CARRILLO MOLINA, Jorge, CLOTET SALA, Bonaventura, and BLANCO ARBUES, Julia M., with IPC classifications A61K 39/42 and C07K 16/10. Protection extends across 30 designated European contracting states including AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.
About this source
GovPing monitors EPO Patent Bulletin - Pharma (A61K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 58 changes logged to date.
What changed
EPO published patent application EP3621649A2, granting Albajuna Therapeutics, S.L. exclusive rights to Fc-fusion protein derivatives designed for HIV treatment with dual antiviral and immunomodulatory functionality. The patent names three inventors and covers two IPC classifications relevant to therapeutic proteins and antiretroviral compositions.
Pharmaceutical and biotechnology entities engaged in HIV therapeutic development should review this patent landscape to assess potential freedom-to-operate considerations. The designated state coverage across 30 European jurisdictions means the IP position is territorially broad within the EU system.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
FC-FUSION PROTEIN DERIVATIVES WITH HIGH DUAL HIV ANTIVIRAL AND IMMUNOMODULATORY ACTIVITY
Publication EP3621649A2 Kind: A2 Apr 15, 2026
Applicants
Albajuna Therapeutics, S.L.
Inventors
CARRILLO MOLINA, Jorge, CLOTET SALA, Bonaventura, BLANCO ARBUES, Julia M.
IPC Classifications
A61K 39/42 20060101AFI20191120BHEP C07K 16/10 20060101ALI20191120BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.